Synta halts study of lung cancer treatment, stock plummets

(Reuters) - Synta Pharmaceuticals Corp has decided to end a late-stage trial of its lung cancer treatment after an independent review said it proved ineffective, nearly halving its stock in extended trading on Tuesday.